Philadelphia, Pennsylvania 19102


Purpose:

Subjects who are ready to start anti-retroviral therapy (ART) will be screened to see if they are eligible for this study. If interested, patient will enroll in this study the same day they are going to start their ART. A blood sample will be obtained that day before they start ART. This sample will be frozen and sent to a special lab at Argos Therapeutics to be stored until the subject's personalized vaccine can be created. We are not certain that a vaccine can be created for everyone. Subjects will be under no obligation to receive the vaccine if it is made.


Criteria:

Inclusion Criteria: - Patients have never taken ARVs,have had a minimum of a twelve week break in regimen,or only as post exposure prophylaxis or for less that 14 days. - Viral load at least 8,000 - CD4 count at least 200 within 30 days of study enrollment Exclusion Criteria: - Prior use of HIV Vaccine - Hepatitis B surface antibody positive - Hepatitis C positive - Positive syphilis - History of or evidence of severe illness/malignancy


NCT ID:

NCT00595192


Primary Contact:

Principal Investigator
Jeffrey M Jacobson, MD
Drexel University College of Medicine

Sharon Lewis, RN,BSN, CCRN
Phone: 215-762-3251
Email: slewis@drexelmed.edu


Backup Contact:

Email: david.downie@drexelmed.edu
David Downie, RN,BSN
Phone: 215-762-1665


Location Contact:

Philadelphia, Pennsylvania 19102
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.